What to hopefully look forward too, page-13

I think it's fair to point to the company itself for the volume at 0.005/6. The price tried to rally off the news but was quickly sold into.

we then had a stock sell down across the bourses. Imo, some cap raise participants found them selves deep in the red on various stocks and sold their free cheap purhases to balance the books. 0.004: was sold into in a big line wipe and a few days later 0.003 (at the same time as 0.001 athos) were wiped.

from a FDA long term view, even if 201 reads at 40% having improved (i imagine this is higher in the earlier disease group), the fact and efficacy come with little to no adverse effects is outstanding. For the, the biggest takeaway from the interim results is that 434 is behaving in humans as it is in animal models.

I hope for those who panic sold that this goes ballistic.